Kate Torchilin

Kate Torchilin is CEO, President and Board Chair of Mirai Bio. She is also a CEO in Residence at Flagship Pioneering. In this role, she provides hands-on leadership across multiple growth-stage companies in partnership with Flagship leaders.

Before joining Mirai and Flagship, Kate served as CEO and a board member of Hamilton Thorne, a public company and a global leader in the assisted reproduction industry. In this role, she drove company growth both organically and through mergers and acquisitions (M&A) from $70M to $200M, and spearheaded a sale of the company, delivering over 60% premium to shareholders.

Prior to Hamilton Thorne, Kate spent 13 years with Thermo Fisher Scientific, starting in Corporate Strategy and M&A, and progressing to become President of the Bioproduction Biologicals and Chemicals division, where she was in charge of a $1.5+ billion global P&L including cell culture media, cell/gene therapy, and GMP chemicals portfolios. Kate represented Thermo Fisher as Executive Sponsor for partnerships with the world’s top pharma companies, including BMS, Roche, Merck, Novartis, Samsung Biologics, Takeda, and Wuxi.

Previously, Kate held executive roles at Alere (now part of Abbot Diagnostics), leading women’s health and connected health, and was founding CEO and board member of Novaseek Research, a health IT and logistics company.

Kate earned a B.S. in Chemistry from Moscow State University, a Ph.D. in Biochemistry from Tufts University, and an MBA from Harvard Business School.